1.1 Type I -the center of the cancer or more than two-thirds of identifiable tumor mass is located >1 cm proximal to the anatomical gastro-esophageal junction 1.2 Type II -the center of the cancer or the tumor mass is located in an area extending one cm proximal to the gastro-esophageal junction to 2 cm distal to it 1.3 Type III -the center of the tumor or more than two-thirds of identifiable tumor mass is located >2 cm below the gastro-esophageal junction 1.4 Barrett's esophagus is identified as an esophagus in which the normal squamous lower esophageal epithelium has been replaced by intestinal type mucosa, which is visible macroscopically.
Type I will be treated as esophageal cancer and types II and III will be treated as gastric cancer. 4.4.1 Gastrectomy. [30] [31] [32] [33] [34] [35] Total gastrectomy was carried out for proximal and mid body gastric tumors with a Roux-en-Y reconstruction to avoid alkaline reflux esophagitis. Distal subtotal gastrectomy for distal gastric tumors (EL-2) with a wide macroscopically negative margin of 5 cm, along with the en bloc resection of lymph nodes (D2 lymphadenectomy, EL-1), [36] [37] [38] and adherent surrounding organs. Spleen and pancreas are spared (EL-2). If a splenectomy is anticipated preoperatively because of tumor adherence shown by CT, we administer pneumococcal polysaccharide, meningococcal, and Haemophilus influenzae vaccines before surgery. 4.4.2 Lymphadenectomy. [36] [37] [38] Resection of lymph nodes in gastric cancer surgery can be carried out at 3 levels: 1) D1, involves removal of all nodal tissue within 3 cm of the primary tumor (perigastric nodes); 2) D2, involves D1 plus clearance of hepatic, splenic, celiac, and left gastric lymph nodes; and 3) D3, involves D2 plus omentectomy, splenectomy, distal pancreatecomy, and clearance of porta hepatis lymph nodes and para-aortic lymph nodes. 4.5 Follow up. There is no consensus regarding follow-up after gastrectomy. There is no evidence that regular intensive follow-up improves patient outcomes. Symptom-driven visits are recommended for most cases (EL-3) 4.6 Post-operative management of residual disease. This will depend on the degree of residual disease as follows: 4.6. 
